HOUSTON, June 30, 2020 /PRNewswire/ -- Marker
Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage
immuno-oncology company specializing in the development of
next-generation T cell-based immunotherapies for the treatment of
hematological malignancies and solid tumor indications, today
announced that it has executed a lease agreement to establish a
cGMP manufacturing facility in Houston,
TX, in an area near the George Bush Intercontinental
Airport. The facility will allow production according to U.S. Food
and Drug Administration (FDA) guidelines and is designed to be
scalable using modular processes. The facility is expected to be
completed by year-end and operational in 2021.
"We are committed to the rapid advancement of Marker's
MultiTAA-specific T cell therapies, which have demonstrated
impressive responses in clinical studies across both hematological
and solid tumors," said Peter L.
Hoang, President & CEO of Marker Therapeutics. "With the
build-out of our own internal manufacturing capabilities, we will
have the flexibility to support our AML trial, and future
hematological and solid tumor trials, as well as the potential
commercialization of our products."
The facility has approximately 48,500 feet and will provide
space for clinical manufacturing and quality functions upon
completion. Marker will continue to manufacture its
MultiTAA-specific T cell therapy at the Baylor
College of Medicine to support the Company-sponsored AML
trial until the in-house cGMP manufacturing facility is
operational.
Commented Anthony Kim, Marker's
Chief Financial Officer: "Commencing the build-out of our internal
cGMP facility strategically fits Marker's expansion plans and is an
exciting next step as we initiate our first Company-sponsored
clinical trial in patients with AML following transplant."
About MultiTAA-Specific T Cell Therapy
Marker's
Multi-Antigen Targeted (MultiTAA) platform is a novel,
non-genetically modified cell therapy approach that selectively
expands tumor-specific T cells from a patient's blood capable of
recognizing a broad range of tumor antigens. In early clinical
trials, the multi-antigen approach has been well tolerated and
shown to enhance tumor destroying capability and is one of the
first therapies to consistently demonstrate epitope spreading –
inducing the patient's own T cells to expand, potentially
contributing to a lasting anti-tumor effect. Unlike other cell
therapies which require pre-conditioning regimens and
hospitalization, MultiTAA is designed to be administered in an
outpatient setting.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology
company specializing in the development of next-generation T
cell-based immunotherapies for the treatment of hematological
malignancies and solid tumor indications. Marker's cell therapy
technology is based on the selective expansion of non-engineered,
tumor-specific T cells that recognize tumor associated antigens
(i.e. tumor targets) and kill tumor cells expressing those targets.
This population of T cells is designed to attack multiple tumor
targets following infusion into patients and to activate the
patient's immune system to produce broad spectrum anti-tumor
activity. Because Marker does not genetically engineer its T cell
therapies, we believe that our product candidates will be easier
and less expensive to manufacture, with reduced toxicities,
compared to current engineered CAR-T and TCR-based approaches, and
may provide patients with meaningful clinical benefit. As a result,
Marker believes its portfolio of T cell therapies has a compelling
product profile, as compared to current gene-modified CAR-T and
TCR-based therapies.
To receive future press releases via email, please
visit: https://www.markertherapeutics.com/email-alerts
Forward-Looking Statement Disclaimer
This release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Statements in this news release concerning the
Company's expectations, plans, business outlook or future
performance, and any other statements concerning assumptions made
or expectations as to any future events, conditions, performance or
other matters, are "forward-looking statements." Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things: our research, development and regulatory
activities and expectations relating to our non-engineered
multi-tumor antigen specific T cell therapies; the effectiveness of
these programs or the possible range of application and potential
curative effects and safety in the treatment of diseases; the
potential benefits of orphan drug designation; the timing and
success of our clinical trials, as well as clinical trials
conducted by our collaborators and our expectations regarding our
manufacturing facility. Forward-looking statements are by their
nature subject to risks, uncertainties and other factors which
could cause actual results to differ materially from those stated
in such statements. Such risks, uncertainties and factors include,
but are not limited to the risks set forth in the Company's most
recent Form 10-K, 10-Q and other SEC filings which are available
through EDGAR at www.sec.gov. The Company assumes no obligation to
update our forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
Contacts
Investors
Solebury Trout
Luke Brown
(646) 378-2944
lbrown@soleburytrout.com
Media
Solebury Trout
Amy Bonanno
(914) 450-0349
abonanno@soleburytrout.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-announces-new-manufacturing-facility-to-support-clinical-development-of-multitaa-specific-t-cell-therapy-product-candidates-301085265.html
SOURCE Marker Therapeutics, Inc.